| Related Articles |
Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteremia: a prospective multi-center cohort study in Korea.
Clin Microbiol Infect. 2017 Jul 07;:
Authors: Lee S, Song KH, Jung SI, Park WB, Lee SH, Kim YS, Kwak YG, Kim YK, Kiem SM, Kim HI, Kim ES, Park KH, Kim NJ, Jang HC, Kim HB, Korea INfectious Diseases (KIND) study group
Abstract
OBJECTIVES: No randomized controlled trials have evaluated the comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.
METHODS: A prospective observational cohort study including all S. aureus bacteremia was conducted at 10 hospitals. Patients (≥15 years) with MSSA bacteremia who received cefazolin or nafcillin as definitive antibiotics were included. The rates of treatment failure (premature discontinuation of antibiotics due to adverse effects, switching of antibiotics due to clinical failure, all-cause mortality within one month, or recurrence) were compared between the cefazolin and nafcillin groups. Propensity score matching analyses were performed to balance the factors influencing the selection of antibiotics.
RESULTS: Among the 242 included cases, the bones and joints (36.8%) were the most common sites of infection and 60.7% of the patients had sepsis. The overall treatment failure rate was 43.8% (106/242). All-cause mortality within one month was 6.2% (15/242). After propensity score matching, the treatment failure rate of cefazolin was lower than that of nafcillin (30.4% [24/79] vs. 49.4% [39/79], p=0.015) due to a higher rate of discontinuation due to adverse events. When the data were limited to patients with sepsis, the treatment failure rates of both groups were not significantly different. Approximately 22% (24/110) of MSSA isolates exhibited cefazolin-inoculum effect (CIE) that had significant impact on the failure rate and mortality of the cefazolin group.
CONCLUSIONS: Cefazolin might be recommended as an adequate and better-tolerated treatment for MSSA bacteremia in the absence of CIE.
PMID: 28694202 [PubMed - as supplied by publisher]